Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India
| Autor: | S. Balasubramanian, Kavipriya Anandhan, C. P. Girish Kumar, Vijaya Lakshmi Nag, Sujata Baveja, Ranganathan N Iyer, P Sulochana Putli Bai, Bhavana J, Balaji Veeraraghavan, Yuvraj Jayaraman, Shrikrishna A Joshi, Pavithra Baskar, Binesh Lal Y, Ayyanraj Neeravi, Rosemol Varghese, Karnika Saigal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Brief Report 030106 microbiology Bacterial pneumonia Erythromycin Clindamycin Biology medicine.disease Azithromycin medicine.disease_cause Microbiology Penicillin 03 medical and health sciences Pneumococcal infections AcademicSubjects/MED00290 0302 clinical medicine Streptococcus pneumoniae medicine AcademicSubjects/MED00740 030212 general & internal medicine AcademicSubjects/MED00230 Ketolide medicine.drug |
| Zdroj: | JAC-Antimicrobial Resistance |
| ISSN: | 2632-1823 |
| DOI: | 10.1093/jacamr/dlab066 |
| Popis: | Background India is among the nations reporting substantial healthcare burden linked to pneumococcal infections. Nafithromycin is a novel lactone ketolide antibiotic, which recently entered Phase 3 development in India for the indication of community-acquired bacterial pneumonia (CABP). Objectives To assess the in vitro activity of nafithromycin against serotyped invasive and non-invasive Streptococcus pneumoniae isolates, collected from nine medical centres across India. Methods A total of 534 isolates of S. pneumoniae were collected during 2015–20 and serotyped as per CDC protocol. A subset of erythromycin-non-susceptible S. pneumoniae (n = 200) was screened for the presence of erm(B) and mef(A/E) genes. A subset of MDR isolates (n = 54) were also subjected to MLST. The MICs of antibiotics were determined by the reference agar-dilution method (CLSI). Susceptibilities of the comparators were interpreted as per CLSI criteria. Results Fifty-nine distinct serotypes were identified among the 534 isolates. Among erythromycin-non-susceptible isolates, erm(B) and mef(A/E) genes were found in 49% and 59% strains respectively, while MLST showed clonal diversity. Azithromycin (67.6% non-susceptible) and clindamycin (31.8% non-susceptible) showed limited activity. Penicillin (for non-meningitis) or quinolone non-susceptibility was low ( Conclusions Indian pneumococcal isolates show poor susceptibilities to macrolides, in concordance with the global trend. Nafithromycin overcomes erm as well as mef-mediated macrolide resistance mechanisms expressed individually or concurrently in S. pneumoniae. This study supports continued clinical development of nafithromycin for pneumococcal infections including CABP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|